According to Mundipharma, the Flutiform fluticasone propionate/formoterol fumarate k-haler breath-activated MDI has received marketing approval through the European decentralized procedure for the treatment of asthma in patients 12 and older. The company had submitted the MAA in March 2016. Flutiform k-haler delivers the same dosages as the existing Flutiform MDI, … [Read more...] about Flutiform k-haler for the treatment of asthma gets European approval
News
Copley Scientific launches TPK 2100 critical flow controller for DPI testing
Inhaler test equipment manufacturer Copley Scientific has launched The TPK 2100, a new model in its TPK series of critical flow controllers for the testing of dry powder inhalers. The company is also launching a new TPK 2100-R with reversed flow inlet and outlets for alternative testing equipment set-ups. The TPK 2100 model's upgrades include a "fly-by-wire" flow … [Read more...] about Copley Scientific launches TPK 2100 critical flow controller for DPI testing
Scammers targeting DDL2017 conference delegates
DDL2017 delegates are being targeted by scammers, organizers warn. Callers claiming to be from the DDL organization have been phoning delegates and offering to book accommodations for the conference and then ask for credit card information. Anyone who has provided credit or debit card details to one of these callers should contact their bank … [Read more...] about Scammers targeting DDL2017 conference delegates
Pulmatrix’s PUR1900 gets additional QIDP designation
Pulmatrix has announced that its PUR1900 itraconazole DPI has received Qualified Infectious Disease Product (QIDP) designation for the treatment of allergic bronchopulmonary aspergillosis (ABPA) in asthma patients. PUR1900 received Orphan Drug designation in 2016 and QIDP status in January 2017 for the treatment of ABPA in cystic fibrosis patients. In September … [Read more...] about Pulmatrix’s PUR1900 gets additional QIDP designation
Impel NeuroPharma appoints Jon Congleton as President and CEO
Intranasal drug developer Impel NeuroPharma has announced the appointment of former Nivalis Therapeutics leader Jon Congleton as the company’s new President and Chief Executive Officer (CEO). Congleton was most recently President and CEO of Nivalis and had previously served in a number of executive roles at Teva. He succeeds an interim CEO, co-Founder John Hoekman, … [Read more...] about Impel NeuroPharma appoints Jon Congleton as President and CEO
Recent advances in inhalation science will be featured at DDL 2017
The 700-plus OINDP specialists expected to convene at the Edinburgh International Conference Centre December 6-8 for this year's Drug Delivery to the Lungs (DDL) meeting will notice a few small changes designed to further the meeting's mission of encouraging inhalation research and to accommodate the growing numbers of delegates and exhibitors, organizers say. One … [Read more...] about Recent advances in inhalation science will be featured at DDL 2017
Synairgen considers developing its inhaled interferon beta for COPD
Synairgen has announced that it is considering development of its SNG001 inhaled interferon beta for the treatment of COPD. SNG001 was previously in development for the prevention of exacerbations caused by viral lung infections in asthma patients. In 2012, the company announced positive results from a Phase 2 study demonstrating that SNG001 produced statistically … [Read more...] about Synairgen considers developing its inhaled interferon beta for COPD
Micro-Sphere adds Harro Höfliger machine for additional DPI capsule filling capacity
CDMO Micro-Sphere has added a Harro Höfliger Modu-C MS capsule filling machine at its Lugano, Switzerland facility as part of a €19 million expansion, the company said, adding that the new machine offers 100% check weight control for accurate DPI capsule filling. Micro-Sphere Founder and President of the Board Michele Müller commented, “Low dose capsule filling is … [Read more...] about Micro-Sphere adds Harro Höfliger machine for additional DPI capsule filling capacity
Engage Therapeutics closes $23 million series A financing round to fund development of inhaled alprazolam
Engage Therapeutics has closed a $23 million Series A financing round led by TPG Biotech that will fund a Phase 2b clinical trial of an inhaled alprazolam for the treatment of acute epileptic seizures. Alexza Pharmaceuticals, which has developed the Staccato alprazolam through Phase 2a, registered the trademark for Engage Therapeutics in 2015. According to one … [Read more...] about Engage Therapeutics closes $23 million series A financing round to fund development of inhaled alprazolam
Frédéric Kahn joins Hovione as VP of Marketing and Sales
CDMO and device company Hovione has announced the appointment of Frédéric Kahn as VP Marketing and Sales. Kahn most recently served as VP Global Head of Key Account Management at Lonza and previously held executive positions at NextPharma and Gerresheimer. Hovione CEO Guy Villax commented, “We are delighted to welcome Mr. Kahn to Hovione. He is an excellent … [Read more...] about Frédéric Kahn joins Hovione as VP of Marketing and Sales